Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
about
Neurochemical changes within human early blind occipital cortex.Brain biochemistry using magnetic resonance spectroscopy: relevance to psychiatric illness in the elderly.Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.Proton MRS in mild cognitive impairment.Magnetic resonance spectroscopy in Alzheimer's disease.A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AβPPswe-PS1dE9 miceMagnetic resonance spectroscopy in common dementiasMagnetic resonance imaging and magnetic resonance spectroscopy in dementiasImaging of Alzheimer's disease.Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease.Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults.Neurochemical changes in the pericalcarine cortex in congenital blindness attributable to bilateral anophthalmia.MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases.Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.1H magnetic resonance spectroscopy in dementia.1H MR spectroscopy in common dementiasLongitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's diseaseThe validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain.Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.Hydrogen proton magnetic resonance spectroscopy in autism: preliminary evidence of elevated choline/creatine ratio.Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.Muscarinic receptor dependent long-term depression in rat visual cortex is PKC independent but requires ERK1/2 activation and protein synthesis.La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease.Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment.Elevated Choline-Containing Compound Levels in Rapid Cycling Bipolar Disorder.
P2860
Q30408825-1026416B-5EF1-40C6-BCBE-CC43A3474DF6Q30585268-90D802B7-16FF-4F94-AD85-3356BD6208BBQ30593705-4B4E7F1B-D8B8-4770-9D5A-0AD6C7A0F43BQ30606675-FAD3D9B0-9C0A-4091-807F-712C83440E76Q30630699-48C59BC1-6C47-4492-86D4-E0CE15CA6F1CQ30635401-F766D893-FEE7-404A-A4B4-37AC66A7DACCQ30660402-DE19F14B-3196-4C55-8223-BACCF682499FQ30660816-C94D4180-A29E-4CF8-927C-A05BCFA68949Q30815106-A889295D-9AF4-416A-8476-1149870E89D2Q30983010-4BD4CB12-6A81-4E8E-AA73-ECA61E152930Q30989943-8B783379-F559-4D78-AFA0-57A10D12F689Q31047131-3C2EDF4A-4380-413D-B9E0-DA78EFC62985Q31159878-BB982E45-8107-4349-8745-D65A7DE06491Q35210272-BCE835BB-ACF4-45E6-90CE-AFACA9C45C82Q36064806-7B25CD44-114D-4793-8C66-12D4429E8711Q36598509-83410EF0-A2AC-4657-BEEC-DF1DB3A26C7FQ36971142-1CF9379C-6AFE-470D-A122-3266BE7D339EQ37150637-11D51EB3-409D-4D4E-827D-CF208838003DQ37398605-0F7A7AAD-E43A-4D8D-8821-B58FC22534B9Q37398634-A2CA9900-72F1-4EE9-8FE9-E5C13E77A784Q37418999-0BFF7594-4729-48DE-AD31-03F0C54858E1Q37459037-1051BE93-54B4-408D-B91B-02ED76A30C0BQ37661367-6D652412-880F-45A9-AD1E-C88D76390AA2Q40285261-91A16481-0C94-47E4-88F4-97E470DEE10BQ41288398-D2646457-60BC-424E-9F56-C9D68D83D7FCQ44043942-15B53F57-931F-4ECA-AFB9-CA7D03195392Q45732943-B46695A9-D54E-4BBB-A311-4A5E17BE8BB7Q48103250-A536FDFA-C200-4CE9-A85C-C6F853BF54E7Q48396205-D838A75C-3664-4E98-898D-628E60B3EFACQ48665796-26803EF3-2F93-4CFE-AA90-C9ED8BDF9688Q53656292-147ABCB7-C21F-4829-8474-608C82918016
P2860
Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Brain proton magnetic resonanc ...... selective cholinergic agonist.
@en
Brain proton magnetic resonanc ...... selective cholinergic agonist.
@nl
type
label
Brain proton magnetic resonanc ...... selective cholinergic agonist.
@en
Brain proton magnetic resonanc ...... selective cholinergic agonist.
@nl
prefLabel
Brain proton magnetic resonanc ...... selective cholinergic agonist.
@en
Brain proton magnetic resonanc ...... selective cholinergic agonist.
@nl
P2093
P356
P1476
Brain proton magnetic resonanc ...... selective cholinergic agonist.
@en
P2093
P304
P356
10.1176/AJP.154.10.1459
P407
P577
1997-10-01T00:00:00Z